Corvus Pharmaceuticals, Inc. Deferred Tax Assets, Tax Credit Carryforwards
Corvus Pharmaceuticals, Inc. (CRVS) had Deferred Tax Assets, Tax Credit Carryforwards of $13.69 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Tax Credit Carryforwards $13.69M.
- 2024-12-31: Deferred Tax Assets, Tax Credit Carryforwards $11.95M.
- 2023-12-31: Deferred Tax Assets, Tax Credit Carryforwards $10.75M.
- 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $9.89M.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards |
|---|---|
| 2025-12-31 | $13.69M 10-K · filed 2026-03-12 |
| 2024-12-31 | $11.95M 10-K · filed 2026-03-12 |
| 2023-12-31 | $10.75M 10-K · filed 2025-03-25 |
| 2022-12-31 | $9.89M 10-K · filed 2025-03-25 |
| 2021-12-31 | $9.18M 10-K · filed 2024-03-19 |
| 2020-12-31 | $7.89M 10-K · filed 2023-03-28 |
| 2019-12-31 | $6.99M 10-K · filed 2022-03-10 |
| 2018-12-31 | $6.44M 10-K · filed 2021-03-25 |
| 2017-12-31 | $4.35M 10-K · filed 2020-03-09 |
| 2016-12-31 | $1.96M 10-K · filed 2019-03-07 |
| 2015-12-31 | $445.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |